NCT02125396

Adjuvant Radiotherapy Comparing TACE for Curative HCC

Adjuvant Radiotherapy Comparing Transarterial Chemoembolization for Curative Hepatocellular Carcinoma: a Randomized Controlled Trials

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Guangxi Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Despite advances in our understanding of hepatocellular carcinoma (HCC) and its diagnosis, the prognosis for patients with HCC remains disheartening, due to a high recurrence rate and frequent intrahepatic metastasis. Various therapies for use after hepatic resection have been reported, but they are associated with adverse side effects or they fail to improve overall survival. Nowadays, adjuvant transarterial chemoembolization (TACE) is recommended as the most effective therapy for postoperative HCC. And the indication is patients with risk factors of recurrence. While more and more prospective studies revealed that radiotherapy is effective for advanced HCC. And the side effects of radiotherapy are controlled. Until now, no prospective or retrospective study compared the efficacy of adjuvant TACE and radiotherapy for postoperative HCC.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
OTHER	Transarterial chemoembolization	Adjuvant transarterial chemoembolization \[5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)\]
OTHER	Radiotherapy	Adjuvant radiotherapy is used for postoperative curative HCC

Timeline

• Start date: 2019-05-01
• Primary completion: 2023-09-01
• Completion: 2023-10-01
• First posted: 2014-04-29
• Last updated: 2023-01-27

Locations

1 site across 1 country: China